Product Description
Albiglutide (Tanzeum) is a glucagon-like peptide 1 (GLP-1) receptor agonist labeled as an adjunct to diet and exercise for the management of type 2 diabetes mellitus in adults. As with other GLP-1 receptor agonists, albiglutide stimulates postmeal insulin secretion and slows gastric emptying to promote satiety (Sourced from: https://www.aafp.org/afp/2017/0415/p521.html)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | European Medicines Agency | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom
Approved Indications: Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes
Known Adverse Events: Back Pain | Pain Unspecified | Respiratory Tract Infections | Arthralgia | Sinusitis | Diarrhea | Influenza, Human
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Type 2 Diabetes|Motion Sickness
Phase 3: Type 2 Diabetes|Kidney Diseases|Respiratory Distress Syndrome, Newborn
Phase 2: Type 1 Diabetes|Heart Failure|Type 2 Diabetes
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CER-4-T2D | N/A |
Active, not recruiting |
Type 2 Diabetes|Kidney Diseases |
2024-07-31 |
|
| NCT03015519 | P3 |
Withdrawn |
Type 2 Diabetes |
2020-04-20 |
|
| Harmony Outcomes | P4 |
Completed |
Type 2 Diabetes |
2020-01-29 |
|
| RDMSTEP | N/A |
Completed |
Type 2 Diabetes |
2018-12-01 |